IDEAYA’s B7-H3 Bispecific ADC Faces Competition as GT Biopharma Doses First NK Engager
B7-H3 antigen has attracted multiple modalities, with IDEAYA advancing bispecific antibody-drug conjugates targeting B7-H3 to compete in an estimated US$362 billion solid tumor market. GT Biopharma dosed the first patient in its Phase 1 subcutaneous GTB-5550 trial on May 14, underscoring growing momentum around this target.
1. B7-H3 Target Opportunity
The B7-H3 protein is broadly overexpressed in prostate, lung, breast, ovarian, head and neck, and pancreatic cancers while largely absent in healthy tissue, creating a potential US$362 billion global solid tumor market. Its correlation with poor prognosis has made it one of the hottest antigens in oncology research for new therapeutic modalities.
2. IDEAYA’s Bispecific ADC Development
IDEAYA is actively developing bispecific antibody-drug conjugates that target B7-H3, aiming to combine targeted delivery with potent payloads to improve efficacy and safety in solid tumors. This program leverages IDEAYA’s expertise in DNA damage response partnerships and ADC technology to address high unmet need in late-line cancer patients.
3. Competitive Landscape and Market Implications
On May 14, GT Biopharma dosed the first patient in its Phase 1 subcutaneous NK cell engager GTB-5550 trial, marking the third TriKE candidate in the clinic and highlighting subcutaneous dosing innovation. The convergence of multiple modalities on B7-H3 could accelerate target repricing and influence IDEAYA’s stock valuation as clinical milestones and competitive differentiation become critical.